Genetic causes of PD: A pathway to disease modification

M Toffoli; S R L Vieira; A H V Schapira

doi:10.1016/j.neuropharm.2020.108022

Genetic causes of PD: A pathway to disease modification

Neuropharmacology. 2020 Jun 15:170:108022. doi: 10.1016/j.neuropharm.2020.108022. Epub 2020 Feb 29.

Authors

M Toffoli¹, S R L Vieira¹, A H V Schapira²

Affiliations

¹ Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom.
² Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom. Electronic address: a.schapira@ucl.ac.uk.

PMID: 32119885
DOI: 10.1016/j.neuropharm.2020.108022

Abstract

The underline neuropathology of Parkinson disease is pleiomorphic and its genetic background diverse. Possibly because of this heterogeneity, no effective disease modifying therapy is available. In this paper we give an overview of the genetics of Parkinson disease and explain how this is relevant for the development of new therapies. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.

Keywords: Disease modifying; GBA1; Genetics; LRRK2; Parkinson disease; SNCA; Therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anticonvulsants / therapeutic use*
Genetic Association Studies / methods*
Genetic Association Studies / trends
Genetic Therapy / methods*
Genetic Therapy / trends
Humans
Immunotherapy / methods*
Immunotherapy / trends
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
Parkinson Disease / genetics*
Parkinson Disease / immunology
Parkinson Disease / therapy*
alpha-Synuclein / genetics

Substances

Anticonvulsants
SNCA protein, human
alpha-Synuclein
LRRK2 protein, human
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Abstract

Publication types

MeSH terms

Substances

Grants and funding